Trials / Completed
CompletedNCT06344351
A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer
A Phase I Study to Evaluate the Safety, Tolerance and Pharmacokinetics of TQB3006 Tablets in Patients With Advanced Malignant Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study includes two stage: dose escalation and dose extension, with a single dose and a multiple dose study. This is a single-center, open, non-randomized, single arm, study to evaluate the safety, tolerability and pharmacokinetics of TQB3006 tables in patients with advanced malignant cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3006 tablets | TQB3006 is an inhibitor protein. |
Timeline
- Start date
- 2024-04-25
- Primary completion
- 2025-05-20
- Completion
- 2025-05-20
- First posted
- 2024-04-03
- Last updated
- 2025-05-22
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06344351. Inclusion in this directory is not an endorsement.